Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Mitral Valve Prolapse. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse: the SCIMITAR Trial
Overview
This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.
Detailed description
Patients with mitral valve prolapse and non-significant mitral regurgitation generally have a good prognosis. A minority of patients with MVP suffers from ventricular arrhythmias. Different demographic, clinical, and electrocardiographic characteristics, as well as morphological and structural features of the MV were described as potential risk factors for ventricular arrhythmias, among which fibrosis of the left ventricular inferolateral wall and posterior papillary muscle as detected by cardiac magnetic resonance.
As cardiac magnetic resonance has some limitations, it is unknown if and which patients with mitral valve prolapse should undergo cardiac magnetic resonance in routine clinical practice, to search for late gadolinium enhancement as a surrogate for myocardial fibrosis.
Primary outcome measures
- Prediction of fibrosis by CMR [Time frame: June 2026]
Secondary outcome measures (6)
- Prediction of ≥ mild Ventricular Arrhythmias and/or Sudden cardiac death in mitral valve [Time frame: June 2026]
- Clinical data [Time frame: June 2026]
- Transthoracic echocardiography parameters: [Time frame: June 2026]
- Rest ECG parameters: [Time frame: June 2026]
- 24h electrocardiographic monitoring parameters: [Time frame: June 2026]
- CMR parameters [Time frame: June 2026]
Eligibility criteria
Inclusion criteria
- age ≥ 18 years
- Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views
Exclusion criteria
- age< 18 years
- coexistence of other cardiomyopathies or other ≥ moderate valve diseases
- scarce acoustic transthoracic echocardiographic window
- usual contraindications for cardiac magnetic resonance
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Centro Cardiologico Monzino — Milan
Identifiers
NCT: NCT06341166 · CCM1959